Fortis Healthcare Delivers Strong FY26 Growth; PAT Surges 31.5%

Fortis Healthcare Limited reported a strong operational and financial performance for FY26, driven by robust growth in its hospital business, diagnostics expansion, and strategic acquisitions. ### Q4 FY26 Highlights 🔹 Revenue rose 17.8% YoY to ₹2,365 Cr 🔹 Operating EBITDA increased 22.2% YoY to ₹531 Cr 🔹 EBITDA Margin improved to 22.5% 🔹 PAT surged 44.2% YoY to ₹271 Cr ### FY26 Highlights 🔹 Revenue climbed 17.3% YoY to ₹9,128 Cr 🔹 Operating EBITDA jumped 31.3% YoY to ₹2,085 Cr 🔹 EBITDA Margin expanded to 22.8% vs 20.4% 🔹 PAT increased 31.5% YoY to ₹1,064 Cr ### Key Business Updates ✅ Hospital business revenue grew 19.1% YoY to ₹7,773 Cr ✅ Diagnostics revenue rose 8.5% YoY to ₹1,527 Cr ✅ International patient revenue increased 18.5% YoY ✅ Added ~500 beds through acquisitions and expansion initiatives ✅ Board recommended dividend of ₹1 per share Fortis continued strengthening its healthcare network through acquisitions, brownfield expansion, and investments in advanced medical technology including robotic surgery systems, MRI machines, and Cath Labs. The company also highlighted strong growth across key specialties including Orthopedics, Renal Sciences, Oncology, and Cardiac Sciences. ⚠️ Disclaimer: This post is for educational and informational purposes only and should not be construed as investment advice or recommendation. $FORTIS